GW&K Investment Management LLC Grows Stake in Vericel Corporation (NASDAQ:VCEL)

GW&K Investment Management LLC lifted its position in Vericel Corporation (NASDAQ:VCEL - Free Report) by 12.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,432,434 shares of the biotechnology company's stock after purchasing an additional 158,470 shares during the period. GW&K Investment Management LLC owned 2.86% of Vericel worth $63,915,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Wellington Management Group LLP increased its position in shares of Vericel by 119.3% during the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock worth $70,775,000 after purchasing an additional 701,064 shares in the last quarter. Champlain Investment Partners LLC acquired a new position in shares of Vericel during the fourth quarter worth $34,233,000. Raymond James Financial Inc. purchased a new stake in shares of Vericel during the fourth quarter valued at $28,126,000. Federated Hermes Inc. grew its holdings in shares of Vericel by 25.4% during the fourth quarter. Federated Hermes Inc. now owns 1,122,373 shares of the biotechnology company's stock valued at $61,630,000 after buying an additional 227,675 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Vericel by 5,916.5% during the first quarter. GAMMA Investing LLC now owns 129,175 shares of the biotechnology company's stock valued at $5,764,000 after buying an additional 127,028 shares during the last quarter.

Vericel Trading Down 2.5%

VCEL stock opened at $35.34 on Monday. The company has a market cap of $1.78 billion, a price-to-earnings ratio of 1,178.39 and a beta of 1.32. Vericel Corporation has a 12 month low of $35.18 and a 12 month high of $63.00. The firm has a 50-day moving average of $41.54 and a two-hundred day moving average of $46.79.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Vericel had a net margin of 1.25% and a return on equity of 1.09%. The firm had revenue of $52.60 million during the quarter, compared to analysts' expectations of $53.86 million. During the same period last year, the company earned ($0.08) EPS. The business's quarterly revenue was up 2.6% on a year-over-year basis. As a group, equities analysts forecast that Vericel Corporation will post 0.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Vericel from a "hold" rating to a "sell" rating in a report on Monday, May 12th. Truist Financial lowered their target price on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Finally, Stephens reissued an "overweight" rating and set a $67.00 target price on shares of Vericel in a research note on Monday, June 16th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to MarketBeat, Vericel has a consensus rating of "Moderate Buy" and an average price target of $61.14.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.